Replay Conf call - Janssen deal & Replay Webcast - ITP Ph2 & AML Ph1/2 data

2012

arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform

December 06, 2012

Breda, the Netherlands, and Ghent, Belgium  – arGEN-X, a biopharmaceutical company focused on the discovery and development of highly differentiated human monoclonal antibody therapeutics has received its first Notice of Allowance from the United States Patent and Trademark Office (USPTO) in connection with a portfolio of patent filings related to its SIMPLE Antibody™ discovery platform.

arGEN-X reveals the target and unique mechanism of action of its most advanced preclinical antibody at the PEGS Summit 2012

November 06, 2012

  • ARGX-110 is highly potent and selective for CD70, a key target in cancer and autoimmune diseases

Breda, the Netherlands and Ghent, Belgium  – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, will disclose the exciting attributes of its most advanced SIMPLE Antibody™ candidate, ARGX-110, at the PEGS Summit, Nov 6-8, 2012 in Vienna, Austria. The exciting potential of ARGX-110 will be presented by Dr Karen Silence, Research Fellow and ARGX-110 project leader.

arGEN-X appoints Dr. David L. Lacey to its supervisory board

October 25, 2012

Breda, the Netherlands and Ghent, Belgium  – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody

October 04, 2012

  • Initial Development Strategy for Highly Potent Antibody Will be Focused on China

LA JOLLA, CA, BREDA, THE NETHERLANDS, and GHENT, BELGIUM  – RuiYi (formerly Anaphore) and arGEN-X BV announced today that arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X.

Cambridge Healthtech Associates™ Announces arGEN-X as Inaugural Signature Award™ Winner

May 14, 2012

  • Signature Award recognizes life sciences companies developing unique technologies

Needham, Massachusetts – Cambridge Healthtech Associates™ (CHA™) today announced that arGEN-X is the winner of its inaugural Signature Award™.

arGEN-X granted first US patent covering its unique NHance™ technology

April 24, 2012

Rotterdam, the Netherlands and Ghent, Belgium  – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has been granted the first patent covering its novel NHance™ technology.

arGEN-X launches NHance™ technology to generate better human antibody therapies

March 19, 2012

  • Adds a second proprietary technology to leverage the power of the SIMPLE Antibody™platform

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X announces today the launch of NHance™, its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics.

arGEN-X appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel

March 19, 2012

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has strengthened its management team with two key hires. Alain Thibault, MD joins the Company as Chief Medical Officer, while Jacobus (Koos) Rasser, PhD, JD will serve as IP Counsel.

arGEN-X enters into a therapeutic antibody alliance with Shire

February 28, 2012

  • Human antibody product collaboration in rare diseases

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire.

arGEN-X advances a third therapeutic antibody program into preclinical development

February 08, 2012

  • ARGX-111 is an anti-c-Met antibody with broad applicability in cancer

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has progressed ARGX-111, its third therapeutic candidate, into formal preclinical development.